Redx Pharma PLC
LSE:REDX
Net Margin
Redx Pharma PLC
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
UK |
R
|
Redx Pharma PLC
LSE:REDX
|
50.2m GBP |
-789%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
770.2B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
404.9B USD |
25%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
206.2B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
179.7B CHF |
25%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
167.5B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
213.1B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
140.9B USD |
13%
|
Redx Pharma PLC
Glance View
Redx Pharma Plc engages in the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. The company is headquartered in Macclesfield, Cheshire and currently employs 71 full-time employees. The company went IPO on 2015-03-27. The Company’s product pipeline includes RXC004 and ROC007. Its lead product candidate RXC004, which is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. RXC004 is in Phase I study in combination with nivolumab (OPDIVO- Bristol Myers Squibb, an anti-PD-1 antibody). The RXC007 is a selective small molecule inhibitor that targets Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) which sits at a nodal point in a cell signaling pathway. RXC007 is used for the treatment of fibrotic diseases.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Redx Pharma PLC's most recent financial statements, the company has Net Margin of -789.1%.